
Anixa Biosciences ANIX
$ 2.9
2.11%
Quarterly report 2025-Q4
added 03-09-2026
Anixa Biosciences P/CF Ratio 2011-2026 | ANIX
Annual P/CF Ratio Anixa Biosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.0144 | -0.00965 | -0.0243 | -0.0211 | -12.2 | 2.44 K | -15.4 | -16 | -7.97 | -15.5 | 20.7 | -17.1 | -14.2 | -12.7 | -32.9 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.44 K | -32.9 | 154 |
P/CF Ratio of other stocks in the Diagnostics research industry
| Issuer | P/CF Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
26.1 | - | -6.23 % | $ 30.6 M | ||
|
Akumin
AKU
|
1.15 | - | -17.87 % | $ 25.9 M | ||
|
Aspira Women's Health
AWH
|
-1.41 | - | -6.19 % | $ 10.5 M | ||
|
Bioventus
BVS
|
8.14 | $ 8.92 | 0.56 % | $ 594 M | ||
|
Brainsway Ltd.
BWAY
|
271 | $ 13.76 | 0.81 % | $ 99.4 M | ||
|
Castle Biosciences
CSTL
|
10.9 | $ 26.01 | 0.68 % | $ 722 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
-47.7 | - | - | $ 562 M | ||
|
DexCom
DXCM
|
17.7 | $ 68.2 | 2.8 % | $ 26.6 B | ||
|
Charles River Laboratories International
CRL
|
10.4 | $ 154.35 | 1.57 % | $ 7.65 B | ||
|
CareDx, Inc
CDNA
|
23.6 | $ 17.52 | 1.18 % | $ 934 M | ||
|
Guardant Health
GH
|
-72.7 | $ 87.53 | 0.4 % | $ 11 B | ||
|
Accelerate Diagnostics
AXDX
|
-0.826 | - | -61.36 % | $ 2.46 M | ||
|
Exact Sciences Corporation
EXAS
|
39.7 | $ 103.87 | 0.01 % | $ 19.6 B | ||
|
Global Cord Blood Corporation
CO
|
0.396 | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
-17.1 | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
-1.63 K | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
-2.94 | - | 0.12 % | $ 80.1 M | ||
|
Fulgent Genetics
FLGT
|
22.2 | $ 15.53 | 3.88 % | $ 470 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
21.8 | - | - | $ 10.7 B | ||
|
Biodesix
BDSX
|
-1.89 | $ 17.01 | -1.62 % | $ 2.21 B | ||
|
ICON Public Limited Company
ICLR
|
12.9 | $ 99.43 | 1.86 % | $ 8.2 B | ||
|
IQVIA Holdings
IQV
|
10.7 | $ 168.32 | 2.14 % | $ 28.9 B | ||
|
Danaher Corporation
DHR
|
23.3 | $ 194.97 | 1.87 % | $ 139 B | ||
|
Biocept
BIOC
|
-0.447 | - | -13.05 % | $ 7.29 M | ||
|
Heska Corporation
HSKA
|
-38.7 | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
-0.162 | - | -20.0 % | $ 1.06 M | ||
|
Illumina
ILMN
|
19.6 | $ 121.42 | 1.79 % | $ 19.3 B | ||
|
Quest Diagnostics Incorporated
DGX
|
12.4 | $ 199.2 | 0.13 % | $ 22.1 B | ||
|
QIAGEN N.V.
QGEN
|
12.6 | - | - | $ 10.6 B | ||
|
Agilent Technologies
A
|
28.3 | $ 113.43 | 1.43 % | $ 34.5 B | ||
|
BioNano Genomics
BNGO
|
-0.0515 | $ 1.12 | 0.66 % | $ 1.42 M | ||
|
DarioHealth Corp.
DRIO
|
-1.43 | $ 9.28 | 10.24 % | $ 263 M | ||
|
NeoGenomics
NEO
|
284 | $ 8.36 | 1.46 % | $ 1.07 B | ||
|
Neogen Corporation
NEOG
|
17.5 | $ 9.24 | 1.43 % | $ 2 B | ||
|
Lantheus Holdings
LNTH
|
13.1 | $ 78.46 | -0.05 % | $ 5.3 B | ||
|
Chembio Diagnostics
CEMI
|
-0.991 | - | 0.22 % | $ 16.8 M | ||
|
Pacific Biosciences of California
PACB
|
-4.48 | $ 1.41 | 3.31 % | $ 423 M | ||
|
Check-Cap Ltd.
CHEK
|
-0.541 | - | - | $ 9.42 M | ||
|
Co-Diagnostics
CODX
|
-1.58 | $ 4.4 | 101.83 % | $ 129 M | ||
|
Medpace Holdings
MEDP
|
18.2 | $ 452.71 | -0.21 % | $ 13.1 B | ||
|
Motus GI Holdings
MOTS
|
-0.0884 | - | -34.28 % | $ 263 K | ||
|
Mettler-Toledo International
MTD
|
29.7 | $ 1 215.3 | 1.35 % | $ 25 B | ||
|
Celcuity
CELC
|
-4.78 | $ 114.14 | -0.66 % | $ 4.5 B | ||
|
DermTech
DMTK
|
-0.551 | - | -11.32 % | $ 2.94 M | ||
|
National Research Corporation
NRC
|
11.9 | $ 17.95 | 3.16 % | $ 402 M | ||
|
Invitae Corporation
NVTA
|
-1.04 | - | - | $ 21.2 M | ||
|
Enzo Biochem
ENZ
|
-0.00219 | - | -8.98 % | $ 14.8 K | ||
|
Natera
NTRA
|
-12.3 | $ 199.43 | 0.89 % | $ 19.6 B | ||
|
OPKO Health
OPK
|
-6.62 | $ 1.2 | 0.42 % | $ 833 M |